Table 4.
Comorbidities during the first IMT after 1 year of follow-up from the SSc diagnosis date from medical claims data in US MarketScan (see Supplementary Appendix 2 for grouping of categories)
| Comorbidity category | Patients who received IMTs, n (%) N = 2404 |
|---|---|
| Lung | 283 (11.8) |
| Overlap syndromea | 201 (8.4) |
| Heart | 128 (5.3) |
| Gastrointestinal | 164 (6.8) |
| Musculoskeletal | 112 (4.7) |
| Infection | 94 (3.9) |
| Skin | 19 (0.8) |
| Fatigue | 37 (1.5) |
| Abnormal blood chemistry | 16 (0.7) |
| Backache | 16 (0.7) |
| Dizziness | 14 (0.6) |
| Headache | 15 (0.6) |
| Anemia | 9 (0.4) |
| Depression or anxiety | 6 (0.3) |
| Endocrine | 6 (0.3) |
| Coexisting conditions | 4 (0.2) |
| Kidney | 4 (0.2) |
| Malignancy | 1 (0.04) |
Data include all patients who received at least one type of treatment
IMT immunomodulatory therapy, SSc systemic sclerosis
aIncludes arthritis, systemic lupus erythematosus, rheumatoid arthritis, mixed connective tissue disease, myositis, Sjögren syndrome, and anti-phospholipid antibody syndrome